LONDON (Alliance News) - Vectura PLC said Monday it has appointed Anne Whitaker as non-executive director of the drug development firm from the start of June.
Whitaker served as president and chief executive officer of Know Bio LLC and its subsidiary Novoclem Therapeutics Inc until recently, having been appointed February 2017. Prior to that she served in a number of senior roles at GlaxoSmithKline PLC and Sanofi SA.
"I am extremely excited to be joining the board of Vectura during this important time for the company," Whitaker said. "I look forward to working closely with the board and senior management to help Vectura fully leverage its differentiated technology and unique integrated capabilities to maximise value for shareholders and, ultimately, for patients."
Vectura Chairman Bruno Angelici said: "I am delighted to welcome Anne to the Vectura Board. As part of our board succession and planning work we have, for some time, been seeking to identify an appropriate Non-Executive Director with current US pharma experience to replace Frank Condella, who has provided such excellent service to the Skyepharma and, subsequently, Vectura boards for over 12 years."
"Anne fits this brief extremely well," Angelici added. Anne's knowledge and experience will, I am sure, be extremely valuable as the company moves forward with its stated strategy to be an industry-leading inhaled drug-device specialist. It is intended that, once Anne's appointment becomes effective on 1st June 2018, and following a reasonable hand over period, Frank Condella will step down from the board. A further announcement will be made at that time."
Shares in Vectura were 3.0% lower at 95.15 pence on Monday.
Glaxosmithkline (GSK)